All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
Bookmark this article
The MPN Hub invited Stefan Constantinescu, De Duve Institute, Brussels, BE, to give a presentation and chair a discussion on his research paper: Secreted mutant calreticulins (CALRs) as rogue cytokines in myeloproliferative neoplasms. MPN Hub Steering Committee members Jean-Jacques Kiladjian, Steffen Koschmieder, Haifa Kathrin Al-Ali, Tiziano Barbui, and Laura Michaelis joined the discussion.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
Constantinescu opens by providing a background on mutant CALRs and outlining the key questions this international study aimed to answer, including whether mutant CALRs are secreted and from which cells.1 Constantinescu goes on to review the results data and the implications the findings may have on future research in myeloproliferative neoplasms. Following this presentation, the committee members discuss the study and the unanswered questions remaining around mutant CALRs.
- Pecquet C, Papadopoulos N, Balligand T, et al. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms. 2023;141(8):917-929. DOI: 10.1182/blood.2022016846
More about...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox